Skip to main content

Table 2 Inclusion criteria for HCS transplantation in various autoimmune diseases

From: Immune ablation and stem-cell therapy in autoimmune disease - Clinical experience

principles Criteria
General Failed best available conventional therapy
  Progressive disease, poor prognosis (for life or organ)
  Reasonable quality of life if autoimmune disease activity
     were arrested
  <60 years old
  Able to withstand HSC transplantation (especially
     cyclophosphamide 4 g/m2)
SSc Diffuse skin disease for <3 years and progressive plus
     other organ involvement
  Modified Rodnan >16 (max 51)
  Diffuse skin disease for >3 years or limited skin and vital
     organ involvement (threatening)
  Mean PAP <50 mmHg, DLCO >45% predicted
  LVEF >50% of normal (on echo), >45% MUGA
  Controlled arrhythmias
  Hypertension controlled by ACE inhibitors
  Serum creatinine <1.5 times normal upper limit
RA Failed: two DMARDS (including methotrexate) + any
     combination of DMARDS + anti-TNF regimen
  Progressive destruction
  Disease duration 2-10 years
MS Disease duration ≥ 1 year
  EDSS between 3.0 and 6.5
  Disability progression sustained for at least 6 months
     during the previous 2 years of:
     ≥ 1.5 EDSS points if entry EDSS between 3.0 and 5.0
     ≥ 1.0 EDSS point if entry EDSS ≥ 5.5
  Primary or secondary progressive MS
  Clinical or MRI activity during the past year
  1. ACE, angiotensin-converting enzyme; DLCO, lung diffusion capacity; DMARD, disease-modifying antirheumatic drug; EDSS, extended disability score system; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; MUGA, multigated image acquisition; PAP, pulmonary artery pressure; TNF, tumour necrosis factor.